Skip to main content
ERAS
NASDAQ Life Sciences

Pan-RAS Glue Hits 69% ORR in Pancreatic Cancer; Phase 3 Moved Up to 1H 2027

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$13.99
Mkt Cap
$4.991B
52W Low
$2.75
52W High
$24.28
52W Position info
409% above low
Off High info
42% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

ERAS has more than doubled off its 52-week low of $2.75.

Summary

Erasca's pan-RAS molecular glue ERAS-0015 posted 44% confirmed ORR in 2L+ KRAS G12X pancreatic cancer at 32 mg once daily (N=25), with 84% of those patients in the third-line-or-later setting and 44% carrying the less sensitive G12R mutation. In the G12D/G12V subtypes that make up roughly 70% of pancreatic cancer, the confirmed ORR was 69% (N=13). Lung cancer data showed 60% confirmed ORR in post-ICI/platinum KRAS G12X NSCLC (N=5), and biliary tract cancer hit 75% (N=4). Safety held up in the expanded population: mostly low-grade treatment-related adverse events, no dose-limiting toxicities, and zero discontinuations at 32 mg; in combination with gemcitabine/nab-paclitaxel, ERAS-0015 cleared the DLT window through 16 mg QD with no DLTs and is now dosing the 24 mg QD cohort, while ERAS-4001 Phase 1 data support a planned 2027 combination trial. The bigger news for the thesis is timing — Erasca now plans a potentially registration-enabling 2L+ NSCLC trial in 1H 2027 and has pulled its Phase 3 1L pancreatic cancer trial forward to 1H 2027, with a Phase 3 1L NSCLC trial in 2H 2027 to 1H 2028. This builds on the August FDA Fast Track designation for ERAS-0015 in metastatic pancreatic cancer and the November 17 Bristol Myers Squibb clinical collaboration, and it lands with $947.8M in cash from the September 30 balance sheet to fund the expanded trial plan. The 8:00 a.m. ET investor call today is where management will take questions on the data.

Updated with an SEC 8-K filing · What changed

Updates

  1. · SEC 8-K — Erasca's ERAS-0015 plus gemcitabine/nab-paclitaxel cleared the DLT window through 16 mg QD with no DLTs and is now dosing the 24 mg QD cohort; ERAS-4001 Phase 1 data support a planned 2027 combination trial.

At the time of this announcement, ERAS was trading at $13.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5B. The 52-week trading range was $2.75 to $24.28. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

ERAS - Latest Insights

ERAS
Nov 20, 2026, 7:05 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $13.75
Real-time Price: $13.98 info
Change: +$0.230 (+2%) info
Market Cap: $4.92B info
ERAS
Nov 17, 2026, 6:40 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $13.99
Real-time Price: $13.98 info
Change: -$0.0100 (-0.07%) info
Market Cap: $4.92B info
ERAS
Nov 12, 2026, 4:03 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $15.78
Real-time Price: $13.98 info
Change: -$1.80 (-11%) info
Market Cap: $4.92B info
ERAS
Nov 12, 2026, 4:01 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $15.78
Real-time Price: $13.98 info
Change: -$1.80 (-11%) info
Market Cap: $4.92B info
ERAS
Aug 24, 2026, 8:15 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $18.11
Real-time Price: $13.98 info
Change: -$4.13 (-23%) info
Market Cap: $4.92B info